Description:
<jats:p>Relaxin/insulin-like family peptide receptor 1 (RXFP1) mediates relaxin’s antifibrotic effects and has reduced expression in the lung and skin of patients with fibrotic interstitial lung disease (fILD) including idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc). This may explain the failure of relaxin-based anti-fibrotic treatments in SSc, but the regulatory mechanisms controlling<jats:italic>RXFP1</jats:italic>expression remain largely unknown. This study aimed to identify regulatory elements of<jats:italic>RXFP1</jats:italic>that may function differentially in fibrotic fibroblasts. We identified and evaluated a distal regulatory region of<jats:italic>RXFP1</jats:italic>in lung fibroblasts using a luciferase reporter system. Using serial deletions, an enhancer upregulating pGL3-promoter activity was localized to the distal region between -584 to -242bp from the distal transcription start site (TSS). This enhancer exhibited reduced activity in IPF and SSc lung fibroblasts. Bioinformatic analysis identified two clusters of activator protein 1 (AP-1) transcription factor binding sites within the enhancer. Site-directed mutagenesis of the binding sites confirmed that only one cluster reduced activity (-358 to -353 relative to distal TSS). Co-expression of FOS in lung fibroblasts further increased enhancer activity.<jats:italic>In vitro</jats:italic>complex formation with a labeled probe spanning the functional AP-1 site using nuclear proteins isolated from lung fibroblasts confirmed a specific DNA/protein complex formation. Application of antibodies against JUN and FOS resulted in the complex alteration, while antibodies to JUNB and FOSL1 did not. Analysis of AP-1 binding in 5 pairs of control and IPF lung fibroblasts detected positive binding more frequently in control fibroblasts. Expression of<jats:italic>JUN</jats:italic>and<jats:italic>FOS</jats:italic>was reduced and correlated positively with<jats:italic>RXFP1</jats:italic>expression in IPF lungs. In conclusion, we identified a distal enhancer of<jats:italic>RXFP1</jats:italic>with differential activity in fibrotic lung fibroblasts involving AP-1 transcription factors. Our study provides insight into<jats:italic>RXFP1</jats:italic>downregulation in fILD and may support efforts to reevaluate relaxin-based therapeutics alongside upregulation of<jats:italic>RXFP1</jats:italic>transcription.</jats:p>